Key facts
- Step Pharma’s last known valuation is $118.0M (Oct 2025).
- It has raised $115.0M; the latest was Later Stage VC ($10.0M) in Feb 2026.
- Notable investors include Bpifrance, European Innovation Council, Agoranov, Kurma Partners, Inserm Transfert — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Step Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Step Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Step Pharma
Developer of proprietary small molecule therapeutics designed for the treatment of autoimmune diseases. The company's therapeutics use a novel class of oral nucleotide synthesis inhibitors that can target CTPS1 (cytidine triphosphate synthase 1) to induce selective modulation of specific immune cell populations such as T and B cells, translating to better efficacy and an improved therapeutic index, enabling healthcare providers in proper treatment of auto-immune diseases.
- Sector
- Healthcare
- HQ
- Saint-Genis-Pouilly, France
- Founded
- 2014
- Employees
- 12
- Website
- step-ph.com/
- Ownership
- Privately Held (backing)
Step Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Step Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Step Pharma in its N-PORT filings yet. We sweep new filings monthly.